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Abstract
The expression of melanoma-associated antigens (MAA) being limited to normal melanocytes and melanomas, MAAs are
ideal targets for immunotherapy and melanoma vaccines. As MAAs are derived from self, immune responses to these may
be limited by thymic tolerance. The extent to which self-tolerance prevents efficient immune responses to MAAs remains
unknown. The autoimmune regulator (AIRE) controls the expression of tissue-specific self-antigens in thymic epithelial cells
(TECs). The level of antigens expressed in the TECs determines the fate of auto-reactive thymocytes. Deficiency in AIRE leads
in both humans (APECED patients) and mice to enlarged autoreactive immune repertoires. Here we show increased IgG
levels to melanoma cells in APECED patients correlating with autoimmune skin features. Similarly, the enlarged T cell
repertoire in AIRE
2/2 mice enables them to mount anti-MAA and anti-melanoma responses as shown by increased anti-
melanoma antibodies, and enhanced CD4
+ and MAA-specific CD8
+ T cell responses after melanoma challenge. We show
that thymic expression of gp100 is under the control of AIRE, leading to increased gp100-specific CD8
+ T cell frequencies in
AIRE
2/2 mice. TRP-2 (tyrosinase-related protein), on the other hand, is absent from TECs and consequently TRP-2 specific
CD8
+ T cells were found in both AIRE
2/2 and AIRE
+/+ mice. This study emphasizes the importance of investigating thymic
expression of self-antigens prior to their inclusion in vaccination and immunotherapy strategies.
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Introduction
Melanomas account for only 4% of dermatological cancers, but
are responsible for 80% of deaths resulting from skin cancer [1].
Moreover, the 5-year survival rate from metastatic melanoma is
only 14% and no effective therapy is yet available against
melanoma. A better understanding of melanoma immunosurveil-
lance is therefore essential to enable the design of better, targeted
melanoma therapies.
The choice of target antigens is key to the success of tumour
vaccination or tumour immunotherapy. Melanoma candidate
antigens include (A) mutated or aberrantly expressed molecules
(e.g. CDK4, MUM-1, beta-catenin) (B) cancer/testis antigens (e.g.
MAGE, BAGE and GAGE) and (C) melanoma- associated
antigens (MAA) [2]. MAAs are self-antigens normally expressed
during the differentiation of melanocytes and play a role in
different enzymatic steps of melanogenesis. However, in trans-
formed melanocytes (melanoma cells), MAAs are often overex-
pressed. The main MAAs are tyrosinase, an enzyme that catalyses
the production of melanin from tyrosine by oxidation, the
tyrosinase-related proteins (TRP-1) and 2 (TRP-2), the glycopro-
tein (gp)100 (silver-gene) and MelanA/MART. It is thought that
the specialized cell biology of melanin synthesis may favour the
loading of MAA peptides into the antigen presentation pathway
[3]. 50% of melanoma patients have tumour-infiltrating lympho-
cytes (TILs) recognising tyrosinase and Melan A, indicating that
these antigens are important in the natural melanoma immuno-
surveillance [2]. Moreover, MAAs are well characterized in mice
and humans, allowing the development of tetramers to detect
antigen-specific immune responses.
However, as MAAs are self-antigens, it is known that the
immune system establishes immunological tolerance to them
either in the thymus or in the periphery. Thymic tolerance, is
achieved by the promiscuous expression of tissue-specific self-
antigens by medullary TECs (mTECs) promoting self-tolerance
and is controlled by the autoimmune regulator AIRE, a
transcriptional regulator of several thousands of genes in mTECs
[4]. However, AIRE’s exact mechanisms of action are only just
being elucidated. Defects in AIRE lead to multiple autoimmune
disorders in mice and patients with APECED (autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy) [5].
APECED patients suffer from a mild immune deficiency leading
to persistent mucosal and cutaneous infections with candida, more
importantly autoimmune dysfunction is observed in many organs
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alopecia.
Thymic selection is leaky and the ensuing autoimmune
repertoire is kept under control by peripheral tolerance mecha-
nisms. Passive peripheral tolerance is induced in T cells by
presenting antigens under tolerogenic conditions. It has been
suggested that AIRE may also play a role in peripheral expression
of tissue-specific antigens [6]. Regulatory T cells (Tregs) represent
another (active) mechanism of peripheral tolerance. It is also still
controversial whether their positive selection is under the control
of AIRE [7].
Our hypothesis is that the autoreactive T cell repertoire may be
important for tumour immunosurveillance. This was tested by
challenging AIRE deficient mice, that have an enlarged and
diverse autoreactive repertoire, with melanoma, and subsequently
characterising their immune responses.
Here, we characterised responses against the self-antigens of this
natural anti-tumour repertoire, and investigated their thymic
selection. Understanding the mechanisms that allow effective
tumour immune responses using the naturally occurring autore-
active repertoire will be important in developing successful tumour
immunotherapies against melanoma.
Results
APECED patients harbour anti-tumour antibodies
The spontaneous immune reactivity towards tumours was tested
with sera obtained from 8 APECED patients, which have a
broader autoreactive repertoire than normal. As some of these
patients had known skin reactivity, we tested for the presence of
IgM and IgG antibodies against 5 different human melanoma cell
lines and other transformed control cell lines (murine or human)
by flow cytometry, and subtracted the background levels obtained
with normal human serum. 5 out of 8 patients had detectable
specific IgM antibodies to at least one human melanoma line,
mostly several, irrespective of whether their symptoms included
skin features or not (Fig. 1A). APECED patients sera also stained
the human rhabdomyosarcoma cell line TE671 and the murine
melanoma B16F10. Such broad reactivity is often seen with low
affinity antibodies, especially IgMs and is not surprising in
APECED patients where a wide range of auto-antibodies has
been described.
When we tested for melanoma-specific IgGs, these were found
in only 5 out of 8 patients (usually without concomitant IgMs)
(Fig. 1B). Interestingly, 4 of these patients displayed clinical
symptoms involving the skin and/or hair follicles, suggesting that
their vitiligo or alopecia may be related to melanocyte destruction.
Two patients had elevated IgG levels to the human rhabdomyo-
sarcoma TE671 cells, but none showed reactivity to the murine
B16F10 melanoma cell line (Fig. 1B).
AIRE deficient mice reject tumours after priming
To test the hypothesis that an expanded autoimmune repertoire
is important in mediating tumour immunosurveillance, we
challenged AIRE
2/2 mice (backcrossed onto C57Bl/6 mice for
10 generations) with the poorly immunogenic, syngeneic melano-
ma line B16F10. Importantly and as described elsewhere, the
autoimmune phenotype is less pronounced in the C57Bl/6 strain
as compared to other strains [8]. Yet, in a proportion of mice, we
found immune infiltrates in several organs, such as stomach and
salivary glands (data not shown). Moreover, ageing AIRE
2/2
females were sterile.
Young adult AIRE
2/2 or littermate controls AIRE
+/+ or
AIRE
+/2 mice were challenged with 2610
5 B16F10 s.c. Usually,
in non-primed naı ¨ve animals, there was no overall significant
difference in tumour growth between the different genotypes.
However, in some experiments, up to 30% of AIRE
2/2 mice
remained tumour-free while all AIRE
+/+ mice developed tumours.
(Fig. 2A). In contrast, when mice were primed with 10
7 lethally
irradiated B16F10 tumour cells 4 weeks prior to challenge with live
tumour cells, up to 80% of AIRE
2/2 mice remained tumour–free
as opposed to only 20% of AIRE
+/+ animals (Fig. 2B). Since we
observed no difference between wild type and heterozygote (het)
mice, the latter were not always included in subsequent
experiments. We occasionally detected a depigmentation of the
fur at the site of tumour cell injection (in approximately 20% of all
mice). In addition, development of a lighter coat colour starting
from the neck and spreading over the whole body could be
detected in AIRE
2/2 mice only (in approximately 20% of these).
To test whether this was a melanoma-specific effect, we also
challenged the AIRE
2/2 mice with the Lewis lung carcinoma 3LL
after priming with 3LL four weeks earlier. No difference in tuour
growth rate was detected between AIRE
2/2 and AIRE
+/+ mice,
probably due to the fast growing nature of the 3LL tumour.
AIRE
2/2 mice produced increased titers of non-
protective anti-tumour antibodies
The detection of antibodies against melanoma in APECED
patients, and the fact that primed AIRE
2/2 mice rejected
B16F10, prompted us to look for B16F10-specific antibodies in
the serum of AIRE
2/2mice. Serum was obtained at time of
sacrifice from naı ¨ve mice, from mice primed with irradiated
B16F10 cells (4 weeks post-priming), and once more from primed
mice 16 days after challenge with alive B16F10 tumour cells.
B16F10 cells were stained with the murine sera and analysed by
flow cytometry. Overall B16F10-specific immunoglobulin (Ig)
levels were significantly increased in the serum of AIRE
2/2 mice
compared to AIRE
+/2 or AIRE
+/+ littermate controls (Fig. 3A).
When specifically stained for IgM and IgG, IgM antibodies were
found significantly increased in AIRE
2/2 mice even before
priming with tumour cells, a trend that was maintained after
tumour challenge. As expected, IgG responses increased signifi-
cantly after tumour challenge (Fig. 3B). No significant changes
were observed after tumour challenge between AIRE
2/2 and
AIRE
+/+ mice. Polyclonal anti-melanoma titers of the isotype-
switched mature IgGs are increased by antigen exposure in both
types of mice, indicating that the relevant T helper cells are
functional in the absence and presence of AIRE. However, IgM
and IgG titers are significantly increased before priming in
AIRE
2/2 mice, as compared to AIRE
+/+ mice suggesting that T
helper cells have been exposed to melanoma antigens, presumably
expressed on melanocytes, before antigenic challenge with
melanoma. This hypothesis is confirmed by the APECED serum
data. We conclude that the rejection of melanoma in primed
animals is not mediated by IgG antibodies, which was also
confirmed by the inability of AIRE
2/2 serum to confer significant
protection against a B16F10 challenge in wild type hosts (data not
shown). Similar IgM and IgG titers (at all three time points) were
found using the 3LL model (data not shown), in which the
AIRE
2/2 mice did not show tumour protection, corroborating
that antibodies probably do not mediate tumour rejection.
AIRE
2/2 display a higher proportion of activated T cells
in lymphoid organs
To test the involvement of T cells in the observed anti-tumour
response in AIRE
2/2 mice, we measured frequencies of activated
CD4
+ and CD8
+ T cells following tumour challenge in lymph
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after tumour challenge, by measuring the frequencies of CD44
+
and CD62L
low cells. While ex vivo neither CD4
+ nor CD8
+ cells
showed a significant downregulation of CD62L (Fig. 4A), CD44
was significantly upregulated on CD4
+ T lymphocytes and in a
fraction of mice on CD8
+ cells (Fig. 4B). We then stimulated
splenocytes from tumour-challenged mice for 48 h with IFNc-
treated B16F10 and then stained with anti-CD62L antibodies.
Treatment of B16F10 with IFNc enhanced MHC class I and II
expression levels significantly (data not shown), and therefore likely
also antigen presentation. Interestingly, after the in vitro culture
period, we observed significantly more activated CD8
+ and CD4
+
T cells among the splenocytes obtained from AIRE
2/2 mice
compared to AIRE
+/+ mice as judged by their loss of CD62L
expression (Fig. 4C, no stimulation). After restimulation, AIRE
2/2
splenocytes showed significantly more CD62L
low cells than
AIRE
+/+ splenocytes (Fig. 4C+ B16F10) suggesting that CD4
+
and to a lesser degree CD8
+ T lymphocytes are activated after
tumour challenge in AIRE
2/2 mice presumably because of less
efficient thymic clonal deletion in the absence of AIRE.
To determine whether tumour protection is mediated by CD4
+
or CD8
+ T cells, we transferred 10
7 CD4
+ T cells or 1.5610
6
CD8
+ T cells from B16F10 challenged AIRE KO or AIRE WT
mice into naı ¨ve hosts, followed by challenge with B16F10 the
following day. Neither transfer offered a significant delay in
tumour growth, although CD4
+ T cells did delay the tumour onset
by a few days, but then all mice succumbed to tumours. It is
Figure 1. APECED patients with skin features have increased anti-melanoma antibody levels. Cell lines were stained with serum obtained
from APECED patients (2.D.G, 3.D.G., 4.U.G., 5.U.C., 6.M.R., 8.S.S., 12.F.M., 14.U.T.) diluted 1/500. Mm9, mm25, sk.mel23, sk.mel28, A2058 are human
melanoma lines, TE671 a human rhabdomyosarcoma, and B16F10 murine melanoma cell line. Background using normal human serum was
substracted and mean fluorescence indicated as follows 2,0.5, +0.5–0.75, ++0.75–1, +++.1. The secondary antibodies used were A anti-human IgM
FITC and B anti-human IgG FITC.
doi:10.1371/journal.pone.0035005.g001
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combination with serum may confer protection.
It has been suggested that the generation of regulatory T cells
(Tregs) may be dependent upon AIRE and that the absence of
AIRE may result in the generation of fewer or less functional
Tregs [7]. A decrease in functional Treg cells would lead to higher
T cell responses, thereby possibly explaining the improved tumour
rejection seen in AIRE
2/2 mice. To investigate this, the
frequencies of Tregs were determined in AIRE
2/2 and littermate
control mice before and after tumour challenge. However, no
differences in the numbers of CD25
+ CD4
+ FoxP3 cells in draining
LN (dLN), TILs and spleen were found between the different
groups (data not shown). The functional capacity of AIRE
2/2
Treg cells was assessed by depleting them prior to tumour
challenge with an anti-CD25 monoclonal Ab (mAb). This led to a
slight improvement in tumour rejection by littermate controls [9],
as expected, but also similarly enhanced tumour rejection by
AIRE
2/2 mice (Figure 5). These results suggest that the numbers
and function of Tregs, inhibiting anti-tumour responses, are
normal in AIRE
2/2 mice. Evidently, the tumour rejection seen in
AIRE
2/2 mice is not due to a lack of regulatory T cells or their
activity alone.
AIRE
2/2 mice mount anti-tumour T cell responses only
against specific tumour self-antigens
To further characterize the anti-tumour response of AIRE
2/2
mice, we analysed the antigen specificity of the T cell populations
found among tumour-infiltrating lymphocytes (TILs) (when
tumours grew) and in dLN. As CD8
+ T cells were activated in
response to tumours (Fig. 4) and MHC class I tetramers are more
readily available, we concentrated on CD8
+ T cell responses.
Antigen-specific CD8
+ T cells were identified by MHC class I
tetramers for MAAs (mouse gp100, TRP-1, TRP-2). Surprisingly,
amongst the TILs of control mice, up to 14% of all CD8
+ T cells
were found to be specific for a single epitope derived from TRP-2
(representative staining shown in Fig. 6A). In the tumour-dLN,
gp100, TRP-1 and TRP-2 -specific CD8
+ T cells were also
detectable, whereas none were found in the spleen. As the majority
of AIRE
2/2 mice remained tumour-free, we measured gp100,
TRP-1 and TRP-2- specific CD8
+ T cells in dLN. In
approximately half the mice, frequencies of either gp100- or
TRP-1-specific CD8
+ cells were increased in AIRE
2/2 mice
compared to those in littermate control mice (Fig. 6C and B).
Higher responses in AIRE
2/2 mice were observed consistently in
several experiments however, due to the wide variations seen
among AIRE
2/2 mice, the difference did not reach statistical
significance.
Notably, we observed a similar frequency of TRP-2-specific
CD8
+ T cell responses in AIRE
2/2 and AIRE
+/+ mice (Fig. 6B).
To elucidate this discrepancy we measured the responses to each
of these antigens in a more controlled system using lentivirus
expressing either the gp100, TRP-2 or gp33 epitopes to stimulate
antigen-specific responses in vivo. The model foreign antigen gp33,
an epitope derived from the LCMV glycoprotein, was included to
address whether tumour rejection by AIRE
2/2 mice could be due
to a generally hyperactive immune system in these. Mice were
challenged once at the base of the tail with the lentivirus and
numbers of specific CD8
+ T cell in the blood were determined by
tetramer staining over 45 days. Examples of these stainings are
shown in the right panels of Figure 7. When challenged with a
foreign antigen, lentiviral priming induced a biphasic immune
response usually peaking after two weeks and 5 weeks [10].
Not surprisingly, naı ¨ve unstimulated control, AIRE ko or wt
mice showed no significant responses to any of the antigens tested
(Fig. 7A–C). As expected AIRE
2/2 and littermate controls
displayed similar CD8
+ T cell numbers in response to lentivirus
expressing the foreign antigen gp33 and in a biphasic pattern
peaking first at around day 15 and then 38. This suggests that
AIRE
2/2 mice are not hyper-reactive, at least not to this
particular foreign antigen with their CD8
+ T cell response
(Fig. 7A).
A similar biphasic response was observed for the MAA self-
antigen TRP-2 and as expected, 2/3 of both AIRE ko and control
mice mounted a TRP-2-specific CD8 response (Fig. 7C) [10].
Following immunization with the lentivirus expressing gp100, 2/3
AIRE ko mice mounted a good response. In contrast only one wt
mouse made even a weak response (Fig. 7B). Together these results
suggest that the expansion of TRP-2-specific T cells is AIRE-
independent and occurs equally in the periphery of AIRE
+/+ and
AIRE
2/2 animals. By contrast, gp100-specific T cells were rare in
littermate control animals, but were readily induced following
lentiviral immunization of AIRE ko mice, suggesting a greater
expansion of gp100-specific T cells in the absence of AIRE.
Figure 2. AIRE
2/2 mice reject tumour more efficiently than
AIRE
+/+ littermate controls mice after priming. A Mice of
indicated genotype were challenged with B16F10, and tumour growth
monitored over 75 days. B As treated in A, but mice were primed with
irradiated B16F10 4 weeks prior to challenge. Curves were compared
with Logrank test with p values indicated. Similar trends were found in
at least 5 different experiments. In each of these experiments between
5 and 10 mice/group were included.
doi:10.1371/journal.pone.0035005.g002
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on thymic expression of those antigens
As T cell responses to gp100 but not TRP-2 were generated
more efficiently in the absence of AIRE, we investigated the
expression of gp100 and TRP-2 mRNA in the thymic epithelium
of young AIRE
+/+ and AIRE
2/2 mice. mRNA was extracted
from flow sorted mTECs (G8.8
highLy51
low) and cTECs (G8.8
high-
Ly51
high) from 3 AIRE
+/+ and 3 AIRE
2/2 mice and gp100 and
TRP-2 mRNA amplified. mRNA from melanoma B16F10 cells
expressing the MAAs gp100 and TRP-2 cells was included as a
positive control and GAPDH was used for normalisation.
By non-quantitative RT-PCR, the RNA extracted from B16F10
yielded bands for TRP-2 and gp100 at the expected sizes (Fig. 8A).
Interestingly TRP-2 mRNA was not at all detected in mTECs
obtained from AIRE
+/+ or AIRE
2/2 mice. However, in this non-
quantitative PCR, gp100 was found equally expressed in both
littermate controls and AIRE
2/2 mice (Fig. 8A). To obtain a
better and quantitative resolution of mRNA levels, we then used
real time qPCR to quantify the MAA expression in the two TEC
subpopulations. The levels of gp100 were highest in mTECs from
littermate controls, and were ,4 fold lower in AIRE
2/2 mTECS.
As reported previously gp100 levels were lower in AIRE
+/+ cTECs
[11], and undetectable in AIRE
2/2 cTECs (Fig. 8B upper graph).
Confirming the RT-PCR, TRP-2 was undetectable in all the TEC
samples tested using qPCR (Fig. 8B lower graph). These findings
may explain why we detected responses to TRP-2 after both
lentiviral and tumour challenges irrespective of AIRE expression,
and why gp100 responses were only detectable in AIRE
2/2 mice.
Discussion
Using AIRE ko mice that have an expanded autoreactive
repertoire, we show that self-antigens alone can protect against a
syngeneic melanoma challenge. Although this has been addressed
before using MAA specific TCR transgenic models [12] [13] [14],
this is the first time that the natural autoreactive TCR repertoire,
unleashed by deficient thymic selection, has been demonstrated to
be effective in melanoma rejection.
Tumour resistance may depend on autoimmune
repertoire
Even though the autoimmunity in AIRE
2/2 mice is milder on
the C57BL/6 background than in other strains [8], this
autoreactive repertoire is sufficient to mediate tumour rejection.
Our own data and other studies show that only a proportion of
AIRE
2/2 mice on the C57BL/6 background develop detectable
autoimmunity to organs such as retina, stomach and salivary gland
[8,15]. Involvement of the skin has not been specifically examined
in mice, but vitiligo and alopecia are prominent features in many
APECED patients (Fig. 1). The heterogeneity of the autoimmune
manifestations clearly also applies to the immune response and
resistance to melanoma cells, seen in only ,half of the mice.
Interestingly, discolouring of the fur and white fur at the injection
site was usually only observed in mice that rejected tumours
Figure 3. Anti-B16F10 antibodies serum levels are elevated. Mice of the indicated genotype were primed with 5610
6 irradiated B16F10 and
challenged with 2.5610
5 live B16F10. A At time of sacrifice (when tumours reached 10 mm
2 or in the case of tumour-free mice after 50 days), serum
was obtained. 1/500 diluted serum was used to stain B16F10. Secondary antibody was an anti-mouse pan Ig APC. B Serum was obtained before
priming, 4 weeks after priming, or 16 days after live tumour challenge and used to stain B16F10. Naı ¨ve littermate controls or unprimed but
challenged controls were included were indicated. Secondary antibodies used were anti-mouse IgM FITC (upper panel) or anti-mouse IgG FITC (lower
panel). * p value by Mann-Whitney test comparing mean fluorescence of serum staining B16F10. These findings were reproduced three times with
similar results with n.10 in each group.
doi:10.1371/journal.pone.0035005.g003
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correlated with effective immune responses. The variation in the
autoimmune symptoms and anti-tumour responses may be due to
the stochastic nature of both AIRE activity and T cell receptor
rearrangement. For example in the non-responding mice, the
relevant tumour antigen-specific TCR may not have been
generated. These stochastic events as well as modifier genes [15]
have been used to explain the notorious heterogeneity in organs
affected even within APECED siblings [7].
Fromourdata we concludethatbothCD4 andCD8 T cellsofthe
immune system are contributing to tumour rejection by the
autoreactive immune repertoire. Anti-tumour antibodies are
increased in AIRE
2/2 mice, but they are not CD4 dependent
(IgM) and are not protective. In contrast, auto-antibodies and auto-
reactiveB cells detectedinthe absence of AIREexpression appearto
be crucial in the murine autoimmune pathology [16]. Notably, auto-
antibodies against the transcription factors SOX9 and SOX10,
important in the development of melanocytes, have been detected in
APECED patients and are highly associated with skin symptoms
such as vitiligo [17]. Similarly, auto-antibodies from APECED
patients also stain the cytoplasm of keratinocytes and melanocyte
nuclei, correlating with alopecia and vitiligo in these patients [18].
The localization of antigens identified so far is intracellular, whereas
here we describe antibodies to melanoma surface molecules.
Whether these antibodies target antigens on non-transformed
melanocytes remains to be confirmed, but if they did, it would help
to explain destruction of these melanocytes by antibodies, which is
more difficult in the case of intracellular antibody targets.
It has been suggested that AIRE controls the positive selection
of Tregs [7]. In the absence of AIRE, a lack of functional
regulatory T cells may therefore explain the improved tumour
rejection [19]. However, when Tregs were removed from
AIRE
2/2 mice, we found a further increase in tumour rejection.
Failure to detect a difference in numbers of regulatory T cells is
reminiscent of other studies using AIRE
2/2 mice. Taken together
we cannot exclude that AIRE may influence regulatory T cell
development, however, the tumour rejection by AIRE
2/2 mice
cannot be solely explained by the lack of functional regulatory T
cells.
We usually found a tumour incidence of ,70% in non-primed
AIRE
2/2 animals and of only ,20% in primed AIRE
2/2
animals (Fig. 2). The fact that AIRE
2/2 mice show increased IgG
titers even before priming suggests that initial priming may have
occurred in the absence of tumours on melanocytes, initiating
some immune response. However, priming with irradiated
melanoma cells may be necessary to provide efficient costimula-
tion through cross-presentation of tumour antigens taken up from
dying cells to initiate a mature and specific response. Such priming
may be required to break the peripheral tolerance of the
autoimmune repertoire. We found previously that a period of 4
Figure 4. AIRE
2/2 mice have increased overall CD4 and CD8 responses after tumour challenge. Mice of indicated genotype were primed
and challenged with B16F10, then splenocytes were isolated, and stained for CD62L or CD44. A Percentage of CD62L
low cells among CD4
+ or CD8
+ T
lymphocytes ex vivo B Percentage of CD44
+ cells among CD4
+ or CD8
+ T lymphocytes ex vivo C Percentage of CD62L
low cells among CD4
+ or CD8
+ T
lymphocytes after in vitro culture with IFNc stimulated B16F10. * p value Mann-Whitney test comparing % of cells with low CD62L among CD4
+ CD3
+
T lymphocytes. This result is representative of two repeats.
doi:10.1371/journal.pone.0035005.g004
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immune system to expand in time to reject challenge doses of live
tumour cells, which otherwise grow into sizeable tumours within
days [20].
A recent report attributed increased responses of AIRE ko mice
to the model antigen hen egg lysozyme to a hyperreactive immune
system [21]. However, the very similar responses we measured
here in AIRE ko and wt mice to a lentivirus–expressed foreign
LCMV epitope strongly argues against any general anti-tumour
CD8
+ T cell-mediated hypereactivity.
Extending our conclusions to other tumours
As B16F10 is a very aggressive tumour, we suspect that the
autoreactive repertoire might be sufficient to fully reject less
aggressive and more immunogenic tumours. We therefore injected
the fibrosarcoma-inducing drug methylcholanthrene (MCA) into
12 AIRE ko and 12 wt mice (data not shown). We only detected a
small difference in tumour incidence between the two groups (42%
in AIRE ko versus 55% of wt mice). However, as recommended by
Schreiber et al [22], we focused on the kinetics of tumour growth.
The first tumours were detected in ko mice at day 159 as opposed
to day 145 in wt mice, i.e a very modest two week delay. The day
at which half of the mice developed tumours (median) was 187
days in wt mice versus 268 days in ko mice. This ,5 months
latency may partly reflect innate NK mediated tumour control.
That full rejection of MCA-induced tumours was not achieved
may be due to the need of priming, though, unfortunately that
would be precluded in this spontaneous model due to individual
variations in MCA induced tumour antigens.
In addition, when the tumours had grown, the mice were
approaching 12 months in age, by when their responsiveness may
be declining, as we have noted to the melanoma B16F10 in
AIRE
2/2 mice. Interestingly, very old AIRE
2/2 mice have an
increased risk of marginal-zone B cell lymphoma and other
hematopoietic irregularities [23]. The uncontrolled and constant
activation of the immune system may eventually lead to
transformation of hematopoietic, in particular lymphoid cells.
We cannot explain why the autoreactive repertoire is unable to
control the development of tumours in older mice. Oral
carcinomas are well known in APECED patients [24]. However,
Figure 5. Depletion of regulatory T cells leads to improved tumour rejection in both AIRE
2/2 and AIRE
+/+ mice. Mice of the indicated
genotype were primed and challenged with B16F10. Three days and one day prior to challenge, mice were treated twice with 0.5 mg of control
antibody GL113 (A), or with regulatory T cell-depleting antibody PC61 (B). Seven days after depletion with PC61 but not GL113 antibodies,
CD4
+CD25
+ cells were reduced by 60% in the blood. Appearance of tumours was measured for 121 days.
doi:10.1371/journal.pone.0035005.g005
Melanoma Immunity Limited by Thymic Selection
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35005their associated chronic candidiasis may be a major confounding
local risk factor as no increased incidence of other carcinomas has
been reported.
We found no protection in AIRE
2/2 mice when we tested this
model with the Lewis lung carcinoma 3LL. It is possible that the
enlarged autoreactive repertoire may confer resistance to mela-
noma and less so to other tumours. The following observations are
consistent with this hypothesis: Firstly, in healthy humans, there is
a large pool of peripheral CD8
+ T cells of naı ¨ve phenotype specific
for Melan-A [25]. Secondly, vitiligo is an autoimmune skin-
depigmenting disorder characterised by loss of epidermal mela-
nocytes. It is frequently observed in melanoma patients [26] and is
associated with a good prognosis [27]. Thirdly certain AIRE single
nucleotide polymorphisms associated with reduced AIRE stability
are significantly more frequent in healthy patients than in
melanoma patients [26] and so are Melan A-specific T cells,
again implying protective effects of AIRE deficiency.
Implications for selection of tumour vaccine targets
We show in this study that gp100-specific T cells were readily
induced in AIRE
2/2 but not in littermate controls, whereas T
cells specific for TRP-2 were induced in both. This difference
correlated with the clear AIRE-dependent expression of gp100 in
TEC [11], and concomitant absence of TRP-2; also with more
robust CD8
+ responsiveness of AIRE
2/2 mice to both gp100
lentivirus (Fig. 7) and tumour challenge. Surprisingly, TRP-2 was
undetectable in both wt and AIRE
2/2 mTECs; however, that
explains the equally strong responses to lentivirus-encoded antigen
in both AIRE
+/+ and AIRE
2/2 mice. As T cells to TRP-2 were
not sufficient to reject the tumour, they are presumably regulated
by peripheral tolerance mechanisms. Indeed, firstly transferred
TRP-2-specific transgenic T cells were not able to reduce
subcutaneous tumour burden [14] unlike TRP-1 and gp100-
specific TCR transgenic T cells [12,13]. Secondly TRP-2 specific
T cells although easily elicited by lentivirally expressed TRP2
express more PD1 and fail to produce cytokines [10]. In summary
we hypothesize that as TRP-2 may not have induced clonal
deletion in the thymus, peripheral tolerance mechanisms are likely
to be in place.
A recent study in human thymus showed that TRP-2 was
expressed in almost all samples tested, albeit with a large variation
in levels of expression, whereas gp100 mRNA was not always
Figure 6. MAA-specific CD8
+ T cells present in TILs and draining LNs. A Wildtype mice were injected with 10
6 live B16F10 and 10 days later,
TILs were isolated and stained for CD8 and TRP-2-specific TCR using tetramers. B and C Mice of indicated genotypes were primed and challenged
with B16F10 cells, then frequencies of gp100, TRP-1 or TRP-2 tetramer positive cells in the CD8
+ T cell population were plotted. Representative of two
similarly conducted experiments.
doi:10.1371/journal.pone.0035005.g006
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expression may just be explained by the stochastic nature of AIRE
activity, and by the differences in the melanin biosynthesis
pathway and melanocyte numbers in human versus murine skin
(mice only have very few melanocytes in their skin).
There are several reports showing AIRE expression in
peripheral cells including DCs and stromal lymph node cells,
although the functional consequences of peripheral AIRE
expression is poorly understood [29]. One such example of a role
of AIRE outside the thymus is the finding by Niki et al that
AIRE
2/2 NOD mice do not destroy their beta cell islets and do
not develop diabetes as predicted but rather produce auto-
antibodies against a protein expressed by acinar cells, another type
of pancreatic cells, and this protein is not under the transcriptional
control of Aire in the thymus [30]. This suggests that Aire may
regulate the survival of autoreactive T cells beyond transcriptional
control of thymic expression, a mechanism that could well operate
here. To add to this complexity, other transcription factors have
been shown to exert a similar role to AIRE in the periphery such
as Deaf [6]. To shed light on this in respect to tumour antigens
demands further investigation.
To our knowledge, this is the first investigation to highlight the
need to know the candidate antigens and their dependence on
AIRE for planning anti-melanoma vaccine strategies. We
conclude that the immune system establishes tolerance to tumour
antigens in at least three ways: (i) To some antigens not expressed
in the thymus, tolerance is maintained solely in the periphery, like
murine TRP-2. (ii) Others like gp100 and several thousand others
[7] are expressed in the thymus under qualitative or quantitative
influences of AIRE. Specific loss of AIRE-dependent thymic
expression of a single antigen leads to the development of
autoimmunity in the organ where this antigen is expressed [31]
[32]. (iii) Yet other antigens may be expressed in the thymus
thanks to other regulators analogous to AIRE. The existence of the
Figure 7. AIRE
2/2 mice do not hyperreact to foreign antigen but respond better to certain melanocyte antigen than AIRE
+/+
littermate controls. Mice of the indicated genotype were injected s.c at the base of the tail with 4610
6 pfu of lentivirus expressing the indicated
peptides. Serial samples of blood cells (left panels) were stained for CD8 and MHC class I tetramers specific for T cells responding to the injected
peptides (example at peak of response in right panels). A LCMV-derived foreign gp33 presented by H-2D
b B mouse TRP-2 presented by H-2K
b C
gp100 presented by H-2D
b.
doi:10.1371/journal.pone.0035005.g007
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reactive protein and GD67 [29] and on a broader level in a study
by Derbinsky et al [33]. However, this categorization demands
further investigation as does the precise role of AIRE in
establishing tolerance. Clearly it is important to know the category
(i to iii) to which the candidate tumour antigen belongs as well as
the peripheral tolerance mechanisms to which it is subject.
It is well known that occasional autoreactive T cells escape
thymic deletion even when AIRE is expressed normally [25]. Why
does the thymus not eliminate these autoreactive T cells to avoid
autoimmunity? The conventional explanation for this leaky thymic
selection is that the broader the T cell repertoire, the more likely it
is to include TCRs cross-reactive with a large variety of foreign
antigens encountered later in life. Fortuitously (or purposefully), a
few of the escapees may help to fight tumours, but some
autoimmune collateral damage (e.g. to normal melanocytes) may
be inevitable. Indeed, there are several examples in humans of
effective spontaneous protective anti-tumour responses accompa-
nied by autoimmune symptoms. For example, autoimmune
paraneoplastic neurological disorders (PND) result from anti-
tumour responses against neuronal antigens that are aberrantly
expressed in cancer cells. Although they may cause autoimmune
neurological damage, the tumour prognosis is often strikingly
better than in tumour patients with no PND [34]. Clearly, T and
B cell responses directed at tumour autoantigens are capable of
rejecting tumours. Whether they were originally selected purpose-
fully to reject tumours needs further confirmation.
Materials and Methods
Ethics statement
Human serum were diagnostic samples obtained with informed
written consent and approved by the local ethics committee USL
8, Cagliari, and Hospital Healthcare Management of Micro-
citemico Hospital, Clinic Pediatric II, Cagliari for the research
project entitled ‘‘APECED, a common disease in the Sardinian
population 1) genotype/phenotype correlation. 2) Early diagno-
sis’’, which includes this study’s research aim.
All animal experiments were approved by Oxford University
institutional review committee and were performed under the
home office project licence PPL 30/2407. Animal suffering was
kept to the minimum according to the Home office guidelines.
Patients
The Sardinian APECED patients were all AIRE R139X
homozygotes. Their clinical details are summarized in [35].
Cells
Cell lines (TE671, B16F10, sk.mel23, sk.mel28, A2058) were
purchased from ATCC. The human melanoma lines mm9 and
mm25 were a kind gift from Vincenzo Cerundolo, Oxford
University [36].
Animals
Mice were bred and housed in Biomedical Services in Oxford
(BMS). They were kept in individual ventilated cages. The AIRE
ko mice and genotyping protocol were kindly provided by the late
Leena Peltonen, Finland and were backcrossed to C57BL/6 mice
Figure 8. Expression of melanocyte antigens in medullary thymic epithelial cells. Medullary or cortical thymic epithelial cells were sorted
by flow cytometry. A RT-PCR was performed on both types of cells using primers for GAPDH, gp100 and TRP-2. B Real time qPCR was performed
using sorted populations. Expression relative to gp100 expression in AIRE
+/+ mTECs is shown for gp100 and TRP-2. Error bars are from duplicates.
doi:10.1371/journal.pone.0035005.g008
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2/2,
AIRE
+/2 and AIRE
+/+ had undergone the same number of
backcrossings and age and sex-matched littermates were used in all
experiments. All animal experiments were approved by Oxford
University institutional review committee and were performed
under the home office project licence PPL 30/2407. Animal
suffering was kept to the minimum according to the Home office
guidelines.
Mouse genotyping
The insertion of the neo-cassette into the AIRE gene was tested
with the following primers:
3.1F 59 TGA GAC AGT TCC TCT GTG TAG CTT TGG
CTG TGG 39
4.1R 59 GGC GCT ACC GGT GGA TGT GAA ATG TGT
39
NEO5.2 59 TCT TGG GAC TTA CCT GGT TTA ACC
TGG GGC TCA CTG 39
Using all three primers and the GO Taq Green Master Mix
(Promega, Madison, WI, USA), the PCR of genomic knock-out
(ko) DNA yielded a 223 bp long fragment on both alleles whereas
the wild type (wt) DNA amplified a 700 bp fragment, and in
heterozygotes both fragments were amplified.
Mouse challenge
B16F10 was grown in RPMI 1640, 10% fetal calf serum, L-
glutamine and antibiotics. Adherent B16F10 were always lifted
with PBS and centrifugation was avoided where possible. Mice
were either challenged s.c. with 2610
5 B16F10 directly or first
primed s.c. with 5 or 10610
6 irradiated B16F10 (12,000 rad) and
then challenged with live B16F10 s.c (all injections in the flank)
after 30 days. Mice were euthanized when their tumours reached
10 mm
3 in size. When challenged with lentivirus, mice were
injected at the base of the tail with 10
7 pfu lentivirus containing
either the irrelevant antigen of LCMV epitope mgp3333–
41(KAVYNFATC) presented by H2-D
b or mTRP-2180–188
(SVDFFVWL) presented by H-2K
b or mgp100 (EGSRNQDWL)
presented on H-2D
b.
Tumour infiltrating lymphocytes
When a maximum tumour size of 10 mm
3 was reached,
B16F10 melanomas were excised, tumour tissue cut into 1 mm
3
pieces and cells isolated either with the gentleMACS dissociator
(according to the manufacturer’s instructions, Miltenyi Biotec,
Bergisch Gladbach, Germany) or with collagenase and DNAse
following a protocol from Quezada et al [37]. Cells were further
gradient-purified on Lymphoprep (Axis-Shield, PoC AS,Oslo,
Norway).
Restimulation of primary cells
In addition to the ex vivo analysis, bulk splenocytes were
restimulated with B16F10 (1:1 ratio) that had upregulated both
MHC class I and II molecules in response to 200 units IFNc for
48 h. Cells were extensively washed prior to addition of
splenocytes.
Serum staining
Sera were used at 1/50, 1/500 and 1/5000 dilutions to stain the
B16F10 cell line. FITC conjugated anti-mouse IgM or IgG
(Invitrogen, Carlsberg, CA, USA) and FITC conjugated anti-
human IgM (Sigma-Aldrich, Gillingham, UK) or IgG (Abcam,
Cambridge, UK) were used to reveal specific staining.
Antibody and tetramer staining
All primary antibodies were purchased from eBioscience (San
Diego, CA, USA) and used at concentrations between 1 and 5 mg/
ml, except for anti-CD62L (from Caltag lab, Burlingham, CA,
USA). Secondary anti-human IgG FITC was purchased from
Sigma-Aldrich (Gillingham, UK) and anti-human IgM FITC from
Abcam (Cambridge, UK). Tetramer staining was performed with
2 mg/ml of gp33 (KAVYNFATA, D
b), gp100 (EGSRNQDWL,
K
b) and TRP-2 (SVDFFVWL, K
b) tetramers and with 2.15 mg/ml
TRP-1 (TWHRYHLL, K
b) tetramer at 37uC for 20 min and
followed by surface marker staining.
Medullary thymic epithelial cells
Thymi from 4–5 weeks old AIRE ko and wt mice were dissected
and disaggregated using the gentleMACS dissociator (Miltenyi,
Germany) using liver or lung protocols provided by manufacturer.
The epithelial cell fraction was enriched by negative selection with
the CD45
+ leukocytes Isolation kit (Miltenyi, Germany). The
unlabelled flow-through was collected and flow cytometry-sorted
using rat anti-G.8.8 (Invitrogen, CA, USA), followed by goat anti-
rat FITC, thoroughly washed, then stained with biotinylated rat
anti-Ly51 and streptavidin PEcy7. mTECs were sorted according
to G8.8
highLy51
low phenotype and G8.8
highLy51
high cells were
sorted as cTECs [11].
RT-PCR and qPCR
Messenger RNA was isolated from cTECs, mTEcs or B16F10
using the RNeasy Micro kit (Qiagen, Hilden, Germany), reverse
transcribed using the Omniscript RT kit (Qiagen, Hilden,
Germany) adding 5 mg (when possible) of denatured RNA to the
kit components according to the manufacturer’s instructions.
The following primers were included in the PCR reaction
(annealing temperature 62uC).
GAPDH forward 59 CCT GGA GAA ACC TGC CAA
GTA T 39
reverse 59 AGA GTG GGA GTT GCT GTT GAA G 39
gp100 forward 59 ACA TTT CAT CAC CAG CAG GGT
GCC 39
reverse 59 AAC AAG TG GGT GCT GGC C 39
TRP-2 forward 59 CCA TTG ATT TCT CTC ACC AAG
GG 39
reverse 59 TCT CTT GCT GCT GAG ACC TGT
CTC 39
For the qPCR, the Taq-Man gene expression system (Applied
Biosystems, Foster City, CA, US) was performed using the pre-
designed probes for TRP-2 (Mm00494496_m1), gp100
(Mm00498996_m1) and GAPDH (Mm99999915_g1). To nor-
malise samples, the Ct value (=the number of PCR cycle in which
the product-specific fluorescence first exceeds background) for
GAPDH was subtracted from Ct value for each gene. The relative
gene expression was then calculated, setting one condition as
standard according to the manufacturer’s formula.
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